BackImageneBio Overview

ImageneBio Current Cash

Latest current cash for IMA: $95M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$94.68M
↑ 62.42% YoYΔ $36.39M vs prior year quarter

Peer trimmed avg / median

Loading

ImageneBio Current Cash History

Loading

ImageneBio vs. peers: Current Cash Comparison

Loading

ImageneBio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ImageneBio (IMA) FAQ

As of the most recent data (June 2026), IMA shows a current cash of $95M. That compares with $58M in the prior-year period — up 62.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IMA's current cash is now $95M (was $58M) — a 62.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ImageneBio is outperforming or lagging.

Tracking IMA's current cash over time shows whether ImageneBio is scaling, shrinking, or reshaping that part of the business. The current reading is $95M That compares with $58M in the prior-year period — up 62.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has ImageneBio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $95M) with ownership activity and broader fundamentals.

ImageneBio's current cash is $95M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.